摘要
目的观察沙利度胺联合FOLFIRI方案治疗晚期结直肠癌的临床疗效和毒副反应。方法沙利度胺200 mg,睡前顿服,d1-10;伊立替康150 mg/m2,静脉滴注90 min,d1;甲酰四氢叶酸(CF)200 mg/m2,静脉滴注2 h,d1-2;5-Fu 400 mg/m2,静脉推注,d1-2;5-Fu 600 mg/m2静脉滴注22 h,d1-2。每2周重复,4周期后评定疗效。结果全组32例均可评价疗效,其中CR 3例(9.38%),PR 15例(46.88%),SD 10例(31.25%),PD 4例(12.50%),总有效率RR(CR+PR)56.25%,1年生存率71.88%。主要毒副反应为腹泻9.38%、白细胞减少46.87%、恶心呕吐28.13%。结论该方案治疗晚期结直肠癌有效率高,明显减轻了毒副反应。
Objective To observe the therapeutic effects and adverse effect of thalidomide combined with FOLFIRI in treatment of advanced intestinal cancers. Methods Thalidomide （200 mg/d, d1 -10） , chemotherapy of regimen; irinoteean 150 mg/m^2 ,90 minutes iv on day 1 ; CF 200 mg/m^2 ,2 hours iv on days 1 to 2; followed by 5-Fu 400 mg/m^2 ,iv and 600 mg/m^2 ,22 hours on days 1 to 2, two weeks as one circle. Efficacy was evaluated after 4 circles. Results 32 patients with advanced intestinal cancers received ,3 patients achieved complete response （CR） , 15 patients partial response（PR） , 10 patients stable disease （SD） , 4 patients progression disease （PD）. Overall response rate was 56.25%. The major toxicity including diarrhea 9.38% ,leucopenia 46.87% , nausea, vomiting 28.13%. Conclusion This study has shown that the regimen of thalidomide combined FOLFIRI is effective and toxicity is reduced clearly in advanced intestinal cancers.
出处
《肿瘤基础与临床》
2008年第6期476-478,共3页
journal of basic and clinical oncology
